Loading viewer...
investor_presentation
Format: PDF investor_presentation
38thAnnual J.P . Morgan Healthcare Conference Howard Robin President & CEO January 13, 2020
J.P . Morgan Healthcare Conference
January 13, 20202This presentation includes forward -looking statements regarding Nektar’s proprietary drug
candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing
and outcome of regulatory decisions, and future availability of clinical trial data. Actual results
could differ materially and these statements are subject to important risks detailed in Nektar's
filings with the SEC including the Form 10 -Q filed on November 7, 2019. Nektar undertakes no
obligation to update forward -looking statements as a result of new information or otherwise.A Robust Pipeline in Multiple Therapeutic Areas
Systemic Lupus Erythematosus NKTR -358
Atopic Dermatitis NKTR -358Chronic Low Back Pain NKTR -181
Metastatic Melanoma Bempegadesleukin (bempeg ) + OPDIVO®
Renal Cell Carcinoma Bempeg + OPDIVO®
Muscle -invasive Bladder Cancer Bempeg + OPDIVO®
Bladder Cancer Bempeg + OPDIVO®
1L NSCLC Bempeg + KEYTRUDA®
Head & Neck SCC Bempeg + Pfizer compounds
Metastatic Prostate Cancer Bempeg + Pfizer compounds
Head & Neck SCC Bempeg + VB10.NEO
Pancreatic Cancer Bempeg + BXCL701
Multiple Solid Tumors NKTR -262 + Bempeg
R/R NHL or Multiple Myeloma NKTR -255 (IL -15)
CD19 CAR -T NKTR -255 (IL -15)
Cancer Immunotherapy NKTR -255 (IL -15)
AA Registrational Study
Virology NKTR -255 (IL -15)
Partner Indication Program Preclinical Phase 1 Phase 2 Phase 3 NDA Filed
Registrational Study
Registrational Study
Registrational Study
Research Collaboration
Research CollaborationPain
Preview truncated — download the full document for the complete content.
conference
28 Pages
investor_presentation
47 Pages
BioLife Solutions
DCM Acquisition RRD Canada Investor Presentation 2023
investor_presentationinvestor_presentation
19 Pages
Data Communications Management Corp.